Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated with Antibody Therapy, Checkpoint Inhibitor in Frontline with ImmunoChemotherapy
- Conditions
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT04745949
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Different Immunosuppressive Treatment in iMN
- Conditions
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT04745728
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT04739813
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 70
- Registration Number
- NCT04734730
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT04729114
- Locations
- 🇺🇸
Northwest Medical Specialties, Tacoma, Washington, United States
🇺🇸First Urology, Jeffersonville, Indiana, United States
🇺🇸Garden Sate Urology, Morristown, New Jersey, United States
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 52
- Registration Number
- NCT04726332
- Locations
- 🇺🇸
Exelixis Clinical Site #2, Dallas, Texas, United States
🇺🇸Exelixis Clinical Site #4, Atlanta, Georgia, United States
🇺🇸Exelixis Clinical Site #3, Boston, Massachusetts, United States
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
- Conditions
- Interventions
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 20
- Registration Number
- NCT04679012
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸Mount Sinai- Icahn School of Medicine, New York, New York, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 115
- Registration Number
- NCT04672512
- Locations
- 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 59
- Registration Number
- NCT04668365
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT04666129
- Locations
- 🇺🇸
Clinical Research Alliance, Inc., Westbury, New York, United States
🇺🇸Arkansas Urology, Little Rock, Arkansas, United States
🇺🇸Alliance Urology, Greensboro, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.